Reportedly, South Africa’s Aspen Pharmacare is to supply the first batch of Johnson & Johnson (JNJ) COVID-19 vaccines to the country from July 26. It is going to be the first set of vaccines to be manufactured in the country from active pharmaceutical ingredients (API), substances that are used to make the final drug product and will be sourced from Europe, Aspen informed.
The country’s vaccination drive suffered in April after U.S. Federal Drug Administration halted production of J&J vaccines at a plant in Baltimore run by Emergent Biosolutions Inc after the doses were found to be contaminated. Under the African Vaccine Acquisition Task Team, the supplies will also be distributed to other African countries as J&J’s has committed to supply 220 million doses of the single-shot vaccine, Aspen informed.
The country has administered just 60 million vaccine doses in a population of 1.3 billion due to restrictions on shipments from vaccine-producing nations. Its dependence on imports of COVID-19 vaccine has left it vulnerable to repeated waves of the coronavirus, raising demands for vaccine production facilities in the continent. South Africa’s Biovac Institute has entered a deal with Pfizer last week for a “fill and finish” arrangement to produce 100 million vaccines by 2022-23.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.